02670nas a2200493   4500000000100000008004100001653001100042653002200053653002000075653003500095653000900130653004100139100001100180700001300191700001500204700001600219700001400235700001200249700001400261700001200275700001600287700001400303700001300317700001700330700001200347700001400359700001500373700001300388700001100401700001500412700001500427700001600442700001600458700001600474700001000490700001300500700001400513700001500527700001200542245010300554856009200657520141300749022001402162       2019                            d10aGender10aGender and health10aGender equality10amass drug administration (MDA)10aNTDs10aSustainable Development Goals (SDGs)1 aCohn D1 aKelly MP1 aBhandari K1 aZoerhoff KL1 aBatcho WE1 aDrabo F1 aNegussu N1 aMarfo B1 aGoépogui A1 aLemoine J1 aGanefa S1 aMassangaie M1 aRimal P1 aGnandou I1 aAnagbogu I1 aNdiaye M1 aBah YM1 aMwingira U1 aAwoussi MS1 aTukahebwa E1 aStelmach RD1 aMingkwan PC1 aPou B1 aKoroma J1 aRotondo L1 aKraemer JD1 aBaker M00aGender equity in mass drug administration for neglected tropical diseases: data from 16 countries.  uhttps://academic.oup.com/inthealth/advance-article/doi/10.1093/inthealth/ihz012/53712113 a<p><strong>BACKGROUND: </strong>Gender equity in global health is a target of the Sustainable Development Goals and a requirement of just societies. Substantial progress has been made towards control and elimination of neglected tropical diseases (NTDs) via mass drug administration (MDA). However, little is known about whether MDA coverage is equitable. This study assesses the availability of gender-disaggregated data and whether systematic gender differences in MDA coverage exist.</p>

<p><strong>METHODS: </strong>Coverage data were analyzed for 4784 district-years in 16 countries from 2012 through 2016. The percentage of districts reporting gender-disaggregated data was calculated and male-female coverage compared.</p>

<p><strong>RESULTS: </strong>Reporting of gender-disaggregated coverage data improved from 32% of districts in 2012 to 90% in 2016. In 2016, median female coverage was 85.5% compared with 79.3% for males. Female coverage was higher than male coverage for all diseases. However, within-country differences exist, with 64 (3.3%) districts reporting male coverage &gt;10 percentage points higher than female coverage.</p>

<p><strong>CONCLUSIONS: </strong>Reporting of gender-disaggregated data is feasible. And NTD programs consistently achieve at least equal levels of coverage for women. Understanding gendered barriers to MDA for men and women remains a priority.</p>
  a1876-3405